TPhreo jeocbt jescutmivme aoryf : Project 1 is to understand the biochemical and cellular mechanisms for terminating endocannabinoid (EC) signaling in the nervous system. The two major ECs, anandamide (AEA) and 2- arachidonoylglycerol (2-AG), are degraded by disfinct enzymatic pathways in vivo. AEA is principally regulated by the integral membrane enzyme fatty acid amide hydrolase (FAAH), which also hydrolyzes several other bioactive fatty acid amides, including the anti-infiammatory lipid A/-palmitoyl ethanolamine, the satiating factor A/-oleoyl ethanolamine, and the TRP channel agonist A/-arachidonoyl taurine. A major challenge in understanding FAAH-regulated fatty acid amide signaling is to discriminate the distinct physiological functions of endogenous FAAH substrates. 2-AG is hydrolyzed by several enzymes in the brain, including the soluble enzyme monoacylglycerol lipase (MAGL) and the integral membrane hydrolases ABHD6 and ABHD12. A major challenge in understanding 2-AG signaling is to determine the unique biochemical and cellular properties of individual 2-AG hydrolytic enzymes. Prior to enzymatic hydrolysis, both AEA and 2-AG may interact with binding proteins responsible for cellular uptake and transport. A major challenge in understanding EC uptake and transport is to identify the putative proteins that mediate these processes. In the previous funding period, we used a combination of synthetic chemistry, enzymology, molecular biology, and functional proteomic/metabolomic methods to enrich our understanding of EC degradative pathways. We have also developed powerful new chemical and genetic tools to probe the function of these pathways. In this renewal application, we plan to use our suite of chemical and genetic tools to gain further mechanistic insights into EC degradative pathways. Specifically, we aim to: 1) characterize mouse models with altered EC degradative pathways, 2) characterize the biochemical and cell biological properties of brain 2-AG hydrolases, and 3) map lipid-protein interactions in EC degradative pathways using chemical proteomic methods. We anticipate that these studies will enhance our understanding of the biochemical pathways that terminate EC signaling in the nervous system and define key components in these pathways that may serve as drug targets for the treatment of a range of human disorders, including pain, depression, and metabolic disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA017259-10
Application #
8484801
Study Section
Human Development Research Subcommittee (NIDA)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
10
Fiscal Year
2013
Total Cost
$489,045
Indirect Cost
$135,368
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Gamage, Thomas F; Ignatowska-Jankowska, Bogna M; Wiley, Jenny L et al. (2014) In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol 25:182-5
Dainese, Enrico; De Fabritiis, Gianni; Sabatucci, Annalaura et al. (2014) Membrane lipids are key modulators of the endocannabinoid-hydrolase FAAH. Biochem J 457:463-72
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-407
Otrubova, Katerina; Cravatt, Benjamin F; Boger, Dale L (2014) Design, synthesis, and characterization of ?-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolase. J Med Chem 57:1079-89
Grim, Travis W; Ghosh, Sudeshna; Hsu, Ku-Lung et al. (2014) Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models. Pharmacol Biochem Behav 124:405-11
Schlosburg, Joel E; Kinsey, Steven G; Ignatowska-Jankowska, Bogna et al. (2014) Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice. J Pharmacol Exp Ther 350:196-204
Naydenov, Alipi V; Horne, Eric A; Cheah, Christine S et al. (2014) ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice. Neuron 83:361-71
Buczynski, Matthew W; Polis, Ilham Y; Parsons, Loren H (2013) The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. Neuropsychopharmacology 38:574-84
Chang, Jae Won; Cognetta 3rd, Armand B; Niphakis, Micah J et al. (2013) Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition. ACS Chem Biol 8:1590-9
Kinsey, Steven G; Wise, Laura E; Ramesh, Divya et al. (2013) Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345:492-501

Showing the most recent 10 out of 111 publications